StockNews.com began coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a report issued on Thursday. The firm issued a hold rating on the stock. Separately, HC Wainwright reiterated a buy rating and issued a $11.00 target price on shares of Galectin Therapeutics in a research note on Tuesday, August 15th. Get Our […]
StockNews com Initiates Coverage on Galectin Therapeutics (NASDAQ:GALT) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
HC Wainwright reissued their buy rating on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a report released on Tuesday morning, Benzinga reports. The firm currently has a $11.00 price target on the stock. HC Wainwright also issued estimates for Galectin Therapeutics’ Q3 2023 earnings at ($0.16) EPS, Q4 2023 earnings at ($0.16) EPS, […]
HC Wainwright Research Analysts Boost Earnings Estimates for Galectin Therapeutics Inc (NASDAQ:GALT) kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
Galectin Therapeutics (NASDAQ:GALT – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $11.00 price objective on the stock. HC Wainwright also issued estimates for Galectin Therapeutics’ Q3 2023 earnings at ($0.16) EPS, Q4 […]